This study, conducted among 5139 British male doctors, aimed to determine whether daily aspirin (500 mg) could reduce the incidence and mortality from stroke, myocardial infarction, or other vascular conditions. The trial lasted six years, with participants followed from November 1978 to November 1984. Two-thirds of the doctors were randomly assigned to take aspirin, while one-third were assigned to avoid it. The primary outcomes included total mortality, non-fatal myocardial infarction, stroke, and other vascular events. Key findings include: - Total mortality was 10% lower in the aspirin group compared to the control group, but this difference was not statistically significant. - There was no significant difference in the incidence of non-fatal myocardial infarction or stroke between the two groups. - The lower incidence limit for the effect of aspirin on non-fatal stroke or myocardial infarction was a substantial 25% reduction. - Migraine and certain types of musculoskeletal pain were reported less frequently in the aspirin group, but the relevance of these findings was difficult to assess due to the lack of a placebo control. - There was no apparent reduction in the incidence of cataract in the aspirin group. The study concluded that while daily aspirin did not significantly reduce the incidence of disabling stroke or vascular death, it may have a substantial effect on reducing the incidence of non-fatal stroke or myocardial infarction. However, the overall results were not definitive, and further evidence from larger trials is needed to confirm the benefits and risks of prophylactic aspirin use in apparently healthy individuals.This study, conducted among 5139 British male doctors, aimed to determine whether daily aspirin (500 mg) could reduce the incidence and mortality from stroke, myocardial infarction, or other vascular conditions. The trial lasted six years, with participants followed from November 1978 to November 1984. Two-thirds of the doctors were randomly assigned to take aspirin, while one-third were assigned to avoid it. The primary outcomes included total mortality, non-fatal myocardial infarction, stroke, and other vascular events. Key findings include: - Total mortality was 10% lower in the aspirin group compared to the control group, but this difference was not statistically significant. - There was no significant difference in the incidence of non-fatal myocardial infarction or stroke between the two groups. - The lower incidence limit for the effect of aspirin on non-fatal stroke or myocardial infarction was a substantial 25% reduction. - Migraine and certain types of musculoskeletal pain were reported less frequently in the aspirin group, but the relevance of these findings was difficult to assess due to the lack of a placebo control. - There was no apparent reduction in the incidence of cataract in the aspirin group. The study concluded that while daily aspirin did not significantly reduce the incidence of disabling stroke or vascular death, it may have a substantial effect on reducing the incidence of non-fatal stroke or myocardial infarction. However, the overall results were not definitive, and further evidence from larger trials is needed to confirm the benefits and risks of prophylactic aspirin use in apparently healthy individuals.